

FORM PTO-1500 (REV. 11-2000)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTORNEY'S DOCKET NUMBER 0760-0290P
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371			U.S. APPLICATION NO. (If known, see 37 CFR 1.5) <b>09/856725</b>
INTERNATIONAL APPLICATION NO. PCT/JP00/06560	INTERNATIONAL FILING DATE September 25, 2000	PRIORITY DATE CLAIMED September 27, 1999	
TITLE OF INVENTION NUCLEIC ACID FRAGMENTS, RECOMBINANT VECTORS CONTAINING THE SAME AND METHOD FOR PROMOTING EXPRESSION OF STRUCTURAL GENES USING THE SAME			
APPLICANT(S) FOR DO/EO/US UEKI, Jun; MORIOKA, Shinji			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<p>1. <input checked="" type="checkbox"/> This is a <b>FIRST</b> submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a <b>SECOND</b> or <b>SUBSEQUENT</b> submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39 (1).</p> <p>4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <p>a. <input type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau).</p> <p>b. <input checked="" type="checkbox"/> has been transmitted by the International Bureau. WO 01/23544</p> <p>c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US).</p> <p>6. <input checked="" type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).</p> <p>a. <input checked="" type="checkbox"/> is transmitted herewith.</p> <p>b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4)</p> <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau).</p> <p>b. <input type="checkbox"/> have been transmitted by the International Bureau.</p> <p>c. <input checked="" type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired.</p> <p>d. <input type="checkbox"/> have not been made and will not be made.</p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).</p> <p>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>			
Items 11. to 20. below concern document(s) or information included:			
<p>11. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98./International Search Report with cited references</p> <p>12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>13. <input checked="" type="checkbox"/> A FIRST preliminary amendment.</p> <p>14. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>15. <input type="checkbox"/> A substitute specification.</p> <p>16. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>17. <input checked="" type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821-1.825.</p> <p>18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</p> <p>19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p> <p>20. <input type="checkbox"/> Other items or information:</p>			

JC18 Rec'd PCT/PTO 25 MAY 2001

U.S. APPLICATION NO. (if known, see 37 CFR 1.5) <div style="font-size: 1.5em; font-weight: bold;">09/856725</div>	INTERNATIONAL APPLICATION NO. PCT/JP00/06560	ATTORNEY'S DOCKET NUMBER 0760-0290P
--	---	--

21 ☒ The following fees are submitted:

**BASIC NATIONAL FEE (37 CFR 1.492(a)(1)-(5)):**

Neither international preliminary examination fee (37 CFR 1.482)  
nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO  
and International Search Report not prepared by the EPO or JPO. .... **\$1,000.00**

International preliminary examination fee (37 CFR 1.482) not paid to  
USPTO but International Search Report prepared by the EPO or JPO. .... **\$860.00**

International preliminary examination fee (37 CFR 1.482) not paid to USPTO  
but international search fee (37 CFR 1.445(a)(2)) paid to USPTO. .... **\$710.00**

International preliminary examination fee (37 CFR 1.482) paid to USPTO  
but all claims do not satisfy provisions of PCT Article 33(1)-(4). .... **\$690.00**

International preliminary examination fee (37 CFR 1.482) paid to USPTO  
and all claims satisfied provisions of PCT Article 33(1)-(4). .... **\$100.00**

**ENTER APPROPRIATE BASIC FEE AMOUNT =**

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30  
months from the earliest claimed priority date (37 CFR 1.492(c)).

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total Claims	24 - 20 =	2	X \$18.00	\$ 72.00
Independent Claims	2 - 3 =	0	X \$80.00	\$ 0
MULTIPLE DEPENDENT CLAIM(S) (if applicable) YES				+ \$270.00 \$ 270.00
<b>TOTAL OF ABOVE CALCULATIONS =</b>				<b>\$ 1202.00</b>

☐ Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are  
reduced by 1/2.

**SUBTOTAL = \$ 1202.00**

Processing fee of \$130.00 for furnishing the English translation later than ☐ 20 ☐ 30  
months from the earliest claimed priority date (37 CFR 1.492(f)).

**TOTAL NATIONAL FEE = \$ 1202.00**

Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be  
accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). **\$40.00 per property** +

**TOTAL FEES ENCLOSED = \$ 1202.00**

	Amount to be:	
	refunded	\$
	charged	\$

a. ☒ A check in the amount of **\$ 1202.00** to cover the above fees is enclosed.


b. ☐ Please charge my Deposit Account. No. \_\_\_\_\_ in the amount of \$ \_\_\_\_\_ to cover the above fees.  
A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any  
overpayment to Deposit Account No. **02-2448**.

**NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR  
1.137(a) or (b)) must be filed and granted to restore the application to pending status.**

Send all correspondence to:  
**Birch, Stewart, Kolasch & Birch, LLP** or Customer No. **2292**  
**P.O. Box 747**  
**Falls Church, VA 22040-0747**  
**(703)205-8000**

**Date: May 25, 2001**

By  #37888  
Gerald M. Murphy, Jr., #28,977

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: UEKI, Jun et al. Conf.:  
Int'l. Appl. No.: PCT/JP00/06560  
Appl. No.: New Group:  
Filed: May 25, 2001 Examiner:  
For: NUCLEIC ACID FRAGMENTS, RECOMBINANT  
VECTORS CONTAINING THE SAME AND  
METHOD FOR PROMOTING EXPRESSION OF  
STRUCTURAL GENES USING THE SAME

PRELIMINARY AMENDMENT

**BOX PATENT APPLICATION**

Assistant Commissioner for Patents  
Washington, DC 20231

May 25, 2001

Sir:

The following Preliminary Amendments and Remarks are respectfully submitted in connection with the above-identified application.

AMENDMENTS

IN THE SPECIFICATION:

Please amend the specification as follows:

Before line 1, insert --This application is the national phase under 35 U.S.C. § 371 of PCT International Application No. PCT/JP00/06560 which has an International filing date of September 25, 2000, which designated the United States of America and was published in Japanese. --

Docket No. 0760-0290P


REMARKS

The specification has been amended to provide a cross-reference to the previously filed International Application.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under 37 C.F.R. § 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By   
Gerald M. Murphy, Jr., #28,977

P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

GMM/ja  
0760-0290P

(Rev. 02/12/01)



09 56725 .062101 7/8

PATENT  
0760-0290P

## IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: UEKI, Jun et al. Conf.: 3445  
Appl. No.: 09/856,725 Group: UNASSIGNED  
Filed: May 25, 2001 Examiner: UNASSIGNED  
For: NUCLEIC ACID FRAGMENTS, RECOMBINANT VECTORS  
CONTAINING THE SAME AND METHOD FOR PROMOTING  
EXPRESSION OF STRUCTURAL GENES USING THE  
SAME.

AMENDMENTHonorable Commissioner of Patents  
Washington, D.C. 20231September 4, 2001  
(Tuesday after Holiday)

Sir:

In response to the Notice to Comply with Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed July 2, 2001, the following Amendments and Remarks are respectfully submitted.

IN THE SPECIFICATION

Please replace the text on page 6, lines 6 and 7 with the following amended text:

5'-aagtcccccg gccgcgccca gcggaag-3' (SEQ ID NO: 4)

3'-gacaccacaca gccgtctata gttcgta-5' (SEQ ID NO: 6)

Please replace the Sequence Listing of record with the Substitute Sequence Listing enclosed herewith.



09/856725.062101

Application No. 09/856,725

REMARKS

Enclosed herewith is a Substitute Sequence Listing to be inserted into the specification as indicated above. The Substitute Sequence Listing in no way introduces new matter into the specification. The Substitute Sequence Listing now includes SEQ ID NO: 6 which appears as a PCR primer on page 6 of the specification. Also submitted herewith is a computer readable form of the Substitute Sequence Listing. The computer readable form of the Substitute Sequence Listing, file "0760-0290P.ST25.txt", is identical to the paper copy, except that it lacks formatting.

Attached hereto is a marked-up version of the changes made to the specification by this amendment.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. \$1.16 or under 37 C.F.R. \$1.17; particularly, extension of time fees.

Respectfully submitted,  
BIRCH, STEWART, KOLASCH & BIRCH, LLP

By *mf/Well* #36,623  
Gerard M. Murphy, Jr., #28,977  
P.O. Box 747  
Falls Church, VA 22040-0747  
(703) 205-8000

<sup>of</sup>  
GMM/BCF  
Enclosures:

Paper and Disk Copy of the Substitute Sequence Listing  
Copy of the Notice to Comply, Version with Markings



09256725.062101

Version With Markings to Show Changes Made

The text on page 6, lines 6 and 7 is amended as shown:

5'-aagtcctcccg gcccgcgcca gcggaag-3' (SEQ ID NO: 4)

3'-gacacccaca gccgtctata gttcgta-5' (SEQ ID NO: 6)



19856725-062101

## SEQUENCE LISTING

<110> Jun UEKI et al.

<120> Nucleic acid fragments, recombinant vectors containing the same and method for promoting expression of structural genes using the same.

<130> 0760-0290P

<140> US 09/856,725

<141> 2001-05-25

<160> 6

<210> 1

<211> 540

<212> DNA

<213> *Oryza sativa*

<400> 1

gttcggagccc	ttctccttaa	tetactcgtc	tttgctcttg	ctctttttct	tttgtgtccc	60
tttcttgtgt	gtgcggtttg	atgagcccg	attgatctg	ctagtgcaca	gtacagtcag	120
atacactgaa	acgatctgga	aattctggat	tattaggaaa	aataaagagg	tagtagacaa	180
gaattggaga	tactttctat	caagattggt	ctattatgct	tggecatttc	ttgtttgacc	240
caagtacttc	tttgaatcta	gagtttgtcg	tgtgtgatgt	ggltgtgtgt	tgtgtcaaca	300
aaaatctcca	ttagtcaaaa	ctgaaatitt	atttattaac	tgacctacta	aaaatgtaga	360
gtctctctgt	tgtgatgtgt	gcttgtgtca	ccaaaaatct	tgatttgata	gagtttttat	420
ttatttatta	actgacctac	tacaaatcta	ttgctgtatg	ctatgtgtgt	ctgtatcacc	480
tgaatgcaa	tgtctctctc	tttgtgttgc	ttgatctaac	acgtgagctc	atgtcaacag	540

<210> 2

<211> 614

<212> DNA

<213> *Oryza sativa*

<400> 2

ccgcgccagc	ggaagcgccc	ccaagttcat	ccgcaaggtt	cggacccttc	tccttaactt	60
actcgtcttt	gctcttgctc	ttttctcttt	gtgctccctt	cttgtgtgtg	cgtttgcatg	120
agcccggaatt	tgatctgcta	gtgcacagta	cagtcagata	cactgaaacg	atctggaaaat	180
ttcggattat	taggaaaaat	aaagaggtag	tagacaagaa	ttggagatac	tttctatcaa	240
gattgtgcta	ttatgcttgg	ccatttcttg	tttgacccca	gtacttcttt	gaatctagag	300
tttgtgtgtg	gtgatgtggt	gtgtgtttgt	gtcaccacaaa	atcttcatta	gtcaaaaactg	360
aaattttatt	tattaactga	cctactaaaa	atgtagagtt	ctctgtgtgt	gatgtgtgct	420
tgtgtcacca	aaaactctga	tttgatagag	tttttattta	tttattaaat	gacctactac	480
aaatctattg	ctgtatgcta	tgtgtgtctg	tatcacctga	aatgcaatgt	cttctctctt	540
gtgtttcttg	atctaacacg	tgagctcatg	tcaacagttt	gtggagggga	ttgaggacac	600
tgtgggtgtc	ggca					614

<210> 3

<211> 173

<212> DNA

<213> *Oryza sativa*

<400> 3

gtaagccacg	tgtgcttagg	ctaagcgcac	tagagcttct	tgtcgtcttg	cttctctctc	60
------------	------------	------------	------------	------------	------------	----



gctcagatct gcttgcttgc ttgcttcgct agaaccctac tctgtgctgc gagggtcgt 120  
gcttcgtctt ccttcctcaa gttcgatctg attgtgtgtg tgggggggcg cag 173

<210> 4  
<211> 27  
<212> DNA  
<213> Oryza sativa

<400> 4  
aagtcctccg gccgcgcga gcggaag 27

<210> 5  
<211> 27  
<212> DNA  
<213> Oryza sativa

<400> 5  
atgcttgata tctgccgaca cccacag 27

<210> 6  
<211> 27  
<212> DNA  
<213> Oryza sativa

<400> 6  
gacacccaca gccgtctata gttcgtgta 27

## SPECIFICATION

Nucleic Acid Fragments, Recombinant Vectors Containing the Same and Method for Promoting Expression of Structural Genes Using the SameTechnical Field

5           The present invention relates to a nucleic acid fragment having an activity to promote expression of a structural gene located at a downstream site thereof, a recombinant vector containing the same, and to a method for expressing the structural gene using the same, as well as to a plant in which expression of a desired structural gene is promoted by the method.

Background Art

10           Promotion of foreign gene expression is the most required technique in applying the genetic engineering technique to plants. One of the techniques is the utilization of DNA fragments. Known DNA fragments which promote expression of foreign genes include some introns (Simpson and Filipowicz 1996. Plant Mol.Biol. 32: 1-41) including an intron of maize alcohol dehydrogenase (Callis et al. Gene & Development 1, 1183-1200 (1987)), as well as the first intron of rice phospholipase D (WO96/30510). Influences of deletion of a part of inner regions of DNA fragments derived from introns, and of insertion of the same intron into the intron, on the promotion of expression have been reported (Mascarenhas et al. Plant Mol. Biol. 15, 913-920 (1990), Clancy et al. Plant Sci.98, 151-161 (1994)).

20           However, so far, types of available DNA fragments are limited. Further, actions of the DNA fragments vary depending on the type of the plant, and vary depending on the organs or tissues even in the same plant (Simpson and Filipowicz 1996. Plant Mol.Biol. 32: 1-41). Therefore, existence of DNA fragments exhibiting various types of expression-promotion actions is desired.

Disclosure of the Invention

Accordingly, an object of the present invention is to provide a novel nucleic

acid fragment having an activity to promote expression of a structural gene located downstream thereof, and to provide a method for promoting expression of the structural gene downstream thereof.

5 The present inventors intensively studied to discover that the second intron of rice PLD gene has a high activity to promote gene expression, thereby completing the present invention.

10 That is, the present invention provides a nucleic acid fragment having the nucleotide sequence shown in SEQ ID NO:1 in the Sequence Listing, or having the same nucleotide sequence as shown in SEQ ID NO:1 except that one or more nucleotides are substituted or deleted, or one or more nucleotides are inserted therein or added thereto, which has an activity to promote expression of a structural gene located downstream thereof. The present invention also provides a nucleic acid fragment having the nucleotide sequence shown in SEQ ID NO:1 in the Sequence Listing, or a nucleic acid fragment which hybridizes with the nucleic acid fragment 15 under stringent conditions, which has an activity to promote expression of a structural gene located downstream thereof. The present invention further provides a recombinant vector which contains the above-described nucleic acid fragment according to the present invention and a structural gene located downstream of the nucleic acid fragment, by which expression of the structural gene is promoted by the 20 nucleic acid fragment. The present invention further provides a method for promoting expression of a structural gene comprising inserting the nucleic acid fragment according to the present invention into a site upstream of the structural gene. The present invention further provides a plant in which expression of a desired structural gene is promoted, and progenies thereof retaining the character.

25 By the present invention, a novel nucleic acid fragment having a high activity to promote expression of a structural gene was provided. As is apparent from the Example below, the activity of the nucleic acid fragment according to the present

invention to promote expression of the structural gene downstream thereof is much larger than that of the known first intron of rice PLD gene, which has the similar function. Therefore, by inserting the nucleic acid fragment of the present invention into a site upstream of the structural gene, expression of the structural gene is much more promoted. Thus, by the present invention, for example, expression of a foreign gene using a recombinant vector may be much more promoted, so that the present invention will make a large contribution in the field of genetic engineering.

#### Best Mode for Carrying out the Invention

As mentioned above, the nucleic acid fragment according to the present invention is a nucleic acid fragment having the nucleotide sequence shown in SEQ ID NO:1 in the Sequence Listing, or having the same sequence as shown in SEQ ID NO:1 except that one or more nucleotides are substituted or deleted, or one or more nucleotides are inserted therein or added thereto, which has an activity to promote expression of a structural gene located downstream thereof.

As mentioned above, the nucleic acid fragments (hereinafter also referred to as "modified nucleic acid fragment" for convenience) having the same nucleotide sequence as shown in SEQ ID NO: 1 except that one or a plurality of nucleotides are substituted or deleted, or except that one or a plurality of nucleotides are inserted or added, which have activities to promote expression of a structural gene located downstream of the nucleic acid fragments are also within the scope of the present invention. In this case, the region in the modified nucleic acid fragment, which corresponds to a region in the sequence shown in SEQ ID NO:1 preferably has a homology of not less than 70%, more preferably not less than 85%, more preferably not less than 95% with the sequence shown in SEQ ID NO:1. The homology of the nucleotide sequence may easily be calculated by using a well-known software such as FASTA. Further, these modified nucleic acid fragments preferably hybridize with the nucleic acid having the nucleotide sequence shown in SEQ ID NO: 1 under

stringent conditions (i.e., hybridization is carried out in an ordinary hybridization solution such as 5 x Denhardt's reagent, 6 x SSC, 0.5% SDS or 0.1% SDS, at 50 to 65°C, preferably in two steps at 50°C and at 60°C, or in four steps at 50°C, 55°C, 60°C and 65°C).

5           The nucleic acid fragments each of which is a part of the nucleic acid fragment having the nucleotide sequence shown in SEQ ID NO:1, which have activities to promote expression of a structural gene located downstream of the nucleic acid fragments are also within the scope of the present invention. Further, nucleic acid fragments obtained by ligating a plurality of the nucleic acid fragments  
10           according to the present invention are also within the scope of the present invention. In this case, the nucleic acid fragments according to the present invention may be directly ligated or an intervening sequence may exist therebetween.

          The nucleic acid according to the present invention may be either DNA or RNA. However, DNA is preferred in view of stability.

15           Since the nucleotide sequence of the nucleic acid fragment according to the present invention has been determined by the present invention and since the nucleic acid fragment is originated from the genome of rice, the nucleic acid fragment may easily be prepared by a nucleic acid-amplification method such as PCR using the genomic DNA of rice as the template. PCR is well-known in the art and a kit and  
20           apparatus therefor are commercially available, so that it can be easily carried out. Further, the above-mentioned modified nucleic acid fragments may be obtained by subjecting the thus obtained nucleic acid fragment to the well-known site-specific mutagenesis.

          In cases where a plurality of nucleic acid fragments according to the present  
25           invention are ligated, a plurality of nucleic acid fragments according to the present invention may be preliminarily ligated, or a nucleic acid fragment according to the present invention may be inserted into a region containing the nucleic acid fragment

according to the present invention.

By inserting the above-described nucleic acid fragment according to the present invention to a site upstream of a structural gene, the expression of the structural gene may be promoted. Structural genes are controlled by a promoter located upstream thereof. The nucleic acid fragment according to the present invention may be inserted either between the promoter and the structural gene or at a site upstream of the promoter, and the former is preferred. In this case, the distance between the nucleic acid fragment according to the present invention and the structural gene may preferably be 0 bp to 1000 bp, and the distance between the promoter and the nucleic acid fragment according to the present invention may also preferably be 0 bp to 1000 bp.

The present invention also provides recombinant vectors obtained by applying the above-described method of the present invention to an expression vector. The recombinant vector according to the present invention may easily be prepared by inserting the nucleic acid fragment according to the present invention and a structural gene of which expression is to be promoted into a cloning site of a commercially available expression vector. Such an expression vector may preferably be one for plants. Various expression vectors for plants are well-known in the art and commercially available. These expression vectors include a replication origin for replication in host cells, a promoter, cloning sites giving restriction sites for inserting foreign genes, and a selection marker such as a drug resistant gene, and usually contain a terminator which stably terminates transcription. In the method of the present invention, any of these known expression vectors may be employed.

#### Example

The present invention will now be described more concretely by way of examples thereof. It should be noted that the present invention is not restricted to the Example.

A DNA fragment having the second intron of rice PLD gene and 37mer exon regions at both ends of the second intron (the nucleotide of this DNA fragment is shown in SEQ ID NO:2 in Sequence Listing) was amplified by PCR using the following primers and a known rice genomic clone (SEQ ID NO:5 of WO95/0934) as the template.

5'-aagtcctcccgaggccgcgccagcggaag-3'

3'-gacacccacagccgtctatagtcgta-5'

The obtained fragments amplified by PCR were digested with Sma I and Eco RV and inserted into the Sma I site of a vector pBI221 commercially available from CLONTECH, which contains a  $\beta$ -glucuronidase (GUS) gene at a downstream site of 35S promoter. Transient expression of the gene was examined by the method of Sheen (Sheen 1991, Plant Cell 3:225-245). That is, the constructed plasmids were introduced into protoplasts isolated from etiolated maize leaves by electroporation, and transient expression of GUS was measured by the above-mentioned method.

For comparison, the first intron (SEQ ID NO:3 in Sequence Listing) of rice PLD gene was amplified by PCR by the method described in WO96/30510 and inserted into the Sma I site of pBI221, followed by introduction of the obtained vector into maize in the similar manner as described above. The expression of GUS was determined. The results are shown in Table 1 below.

Table 1

Plasmid	GUS Activity (4-MU pmol/10 <sup>7</sup> cells/min)
pBI221 (35S promoter, GUS)(Comparative Example)	140
pBI221 + PLD first intron (Comparative Example)	630
pBI221 + PLD second intron (Example)	11,000

As is apparent from these results, the activity of the nucleic acid fragment according to the present invention to promote expression of the structural gene located downstream thereof is much higher than that of the first intron of rice PLD, which is known to have the similar function.

## CLAIMS

1. A nucleic acid fragment having the nucleotide sequence shown in SEQ ID NO:1 in the Sequence Listing, or having the same nucleotide sequence as shown in SEQ ID NO:1 except that one or more nucleotides are substituted or deleted, or one or more nucleotides are inserted therein or added thereto, which has an activity to promote expression of a structural gene located downstream thereof.
2. The nucleic acid fragment according to claim 1, which has a nucleotide sequence homology of not less than 70% to the nucleotide sequence shown in SEQ ID NO:1 in the Sequence Listing.
3. A nucleic acid fragment having the nucleotide sequence shown in SEQ ID NO:1 in the Sequence Listing, or a nucleic acid fragment which hybridizes with the nucleic acid fragment under stringent conditions, which has an activity to promote expression of a structural gene located downstream thereof.
4. The nucleic acid fragment according to claim 1, which has the nucleotide sequence shown in SEQ ID NO:1 in the Sequence Listing or a part thereof that has an activity to promote expression of a structural gene located downstream thereof.
5. The nucleic acid fragment according to claim 4, which has the nucleotide sequence shown in SEQ ID NO:1 in the Sequence Listing.
6. The nucleic acid fragment according to claim 1, which has the nucleotide sequence shown in SEQ ID NO:2 in the Sequence Listing.
7. A recombinant vector comprising said nucleic acid fragment according to any one of claims 1 to 6, and a structural gene located downstream of said nucleic acid fragment, by which expression of said structural gene is promoted by said nucleic acid fragment.
8. A method for promoting expression of a structural gene comprising inserting said nucleic acid fragment according to any one of claims 1 to 6 into a site upstream of said structural gene.



9. A plant in which expression of a desired structural gene is promoted by the method according to claim 7, or a progeny thereof retaining the character.

## ABSTRACT

A novel nucleic acid fragment which has an high activity to promote expression of a structural gene located downstream thereof, and a method for promoting expression of the structural gene located downstream thereof using the nucleic acid are disclosed. A nucleic acid fragment having the nucleotide sequence shown in SEQ ID NO:1 in the Sequence Listing, and nucleic acid fragments having the same sequence as shown in SEQ ID NO:1 except that one or more nucleotides are substituted or deleted, or one or more nucleotides are inserted therein or added thereto, which have activities to promote expression of a structural gene located downstream thereof were provided.

09856725.062101

Attorney Docket No.

## BIRCH, STEWART, KOLASCH &amp; BIRCH, LLP

P.O. Box 747 · Falls Church, Virginia 22040-0747  
Telephone: (703) 205-8000 · Facsimile: (703) 205-8050COMBINED DECLARATION AND POWER OF ATTORNEY  
FOR PATENT AND DESIGN APPLICATIONS

As a below named inventor, I hereby declare that: my residence, post office address and citizenship are as stated next to my name; that I verily believe that I am the original, first and sole inventor (if only one inventor is named below) or an original, first and joint inventor (if plural inventors are named below) of the subject matter which is claimed and for which a patent is sought on the invention entitled: Nucleic Acid Fragments, Recombinant Vectors Containing the Same and Method for Promoting Expression of Structural Genes Using the Same.

The specification of which is attached hereto. If not attached hereto,

the specification was filed on \_\_\_\_\_ as  
United States Application Number \_\_\_\_\_ (if applicable) and/or  
and amended on \_\_\_\_\_ as PCT  
the specification was filed on 09/25/00 \_\_\_\_\_ and was  
International Application Number PCT/JP00/06560 \_\_\_\_\_  
amended under PCT Article 19 on \_\_\_\_\_ (if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, §1.56.

I do not know and do not believe the same was ever known or used in the United States of America before my or our invention thereof, or patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to this application, that the same was not in public use or on sale in the United States of America more than one year prior to this application, that the invention has not been patented or made the subject of an inventor's certificate issued before the date of this application any country foreign to the United States of America on an application filed by me or my legal representative or assigns more than twelve months (six months for designs) prior to this application, and that no application for patent or inventor's certificate on this invention has been filed in any country foreign to the United States of America prior to this application by me or my legal representatives or assigns, except as follows.

I hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Prior Foreign Application(s)	Priority Claimed
271762/99 (Number)	Japan (Country)
	09/27/99 (Month/Day/Year Filed)
	Yes
(Number)	(Country)
	(Month/Day/Year Filed)

I hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.

(Application Number)	(Filing Date)
(Application Number)	(Filing Date)

All Foreign Applications, if any, for any Patent or Inventor's Certificate Filed More than 12 Months (6 Months for Designs) Prior to the Filing Date of This Application:

Country	Application Number	Date of Filing (Month/Day/Year)

I hereby claim the benefit under Title 35, United States Code, §120 of any United States and/or PCT application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States and/or PCT application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose information which is material to the patentability as defined in Title 37, Code of Federal Regulations, §1.56 which become available between the filing date of the prior application and the national or PCT international filing date of this application.

(Application Number)	(Filing Date)	(Status - patented, pending, abandoned)
(Application Number)	(Filing Date)	(Status - patented, pending, abandoned)

## Attorney Docket No.

I hereby appoint the following attorneys to prosecute this application and/or an international application based on this application and to transact all business in the Patent and Trademark Office connected therewith and in connection with the resulting patent based on instructions received from the entity who first sent the application papers to the attorneys identified below, unless the inventor(s) or assignee provides said attorneys with written notice to the contrary:

(18) Raymond C. Stewart  
Joseph A. Kolasch  
Bernard L. Sweeney  
Charles Gorenstein  
Leonard R. Svensson  
Andrew D. Melike  
Joe McKinney Muncy  
John W. Bailey  
Gary D. Yacura

(Reg. No. 21,066)  
(Reg. No. 22,463)  
(Reg. No. 24,448)  
(Reg. No. 27,277)  
(Reg. No. 30,330)  
(Reg. No. 32,660)  
(Reg. No. 32,334)  
(Reg. No. 32,331)  
(Reg. No. 35,416)

Terrell C. Birch  
James M. Slattery  
Michael K. Mutter  
Gerald M. Murphy, Jr.  
Terry L. Clark  
Marc S. Weiner  
Donald J. Daley  
John A. Castellano

(Reg. No. 19,382)  
(Reg. No. 28,380)  
(Reg. No. 29,860)  
(Reg. No. 28,977)  
(Reg. No. 32,664)  
(Reg. No. 32,151)  
(Reg. No. 34,319)  
(Reg. No. 35,094)

Send Correspondence to:

**BIRCH, STEWART, KOLASCH & BIRCH, LLP** or

Customer No. 2292

P.O. Box 747 · Falls Church, Virginia 22040-0747

Telephone: (703) 205-8000 · Facsimile: (703) 205-8050

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

1-00 GIVEN NAME/FAMILY NAME <b>Jun UEKI</b>	INVENTOR'S SIGNATURE <i>Jun Ueki</i>	DATE* May 22, 2001
Residence (City, State & Country) <b>Iwata-gun, Shizuoka, JAPAN</b>		CITIZENSHIP <b>Japanese JPX</b>
POST OFFICE ADDRESS (Complete Street Address including City, State & Country) <b>c/o Japan Tobacco Inc., Plant Breeding and Genetics Research Laboratory, 700, Higashibara, Toyoda-cho, Iwata-gun, Shizuoka 438-0802 JAPAN</b>		
2-00 GIVEN NAME/FAMILY NAME <b>Shinji MORIOKA</b>	INVENTOR'S SIGNATURE <i>Shinji Moriooka</i>	DATE* May 22, 2001
Residence (City, State & Country) <b>Iwata-gun, Shizuoka, JAPAN</b>		CITIZENSHIP <b>Japanese JPX</b>
POST OFFICE ADDRESS (Complete Street Address including City, State & Country) <b>c/o Japan Tobacco Inc., Plant Breeding and Genetics Research Laboratory, 700, Higashibara, Toyoda-cho, Iwata-gun, Shizuoka 438-0802 JAPAN</b>		
GIVEN NAME/FAMILY NAME	INVENTOR'S SIGNATURE	DATE*
Residence (City, State & Country)		CITIZENSHIP
POST OFFICE ADDRESS (Complete Street Address including City, State & Country)		
GIVEN NAME/FAMILY NAME	INVENTOR'S SIGNATURE	DATE*
Residence (City, State & Country)		CITIZENSHIP
POST OFFICE ADDRESS (Complete Street Address including City, State & Country)		
GIVEN NAME/FAMILY NAME	INVENTOR'S SIGNATURE	DATE*
Residence (City, State & Country)		CITIZENSHIP
POST OFFICE ADDRESS (Complete Street Address including City, State & Country)		

\*DATE OF SIGNATURE

1 / 3

## SEQUENCE LISTING

&lt;110&gt; JAPAN TOBACCO INC.

<120> Nucleic acid fragments, recombinant vectors containing the same a  
nd method for promoting expression of structural genes using the same

&lt;130&gt; OOPF210-PCT

&lt;160&gt; 5

&lt;210&gt; 1

&lt;211&gt; 540

&lt;212&gt; DNA

<213> *Oryza sativa*

&lt;400&gt; 1

```

gttcggacc ttctccttaa tctactcgtc ttgtctcttg ctctttttct ttgtgtgcc 60
tttcttgtgt gtgcgtttgc atgagccga atttgatctg ctagtgcaca gtacagtcag 120
atacactgaa acgatctgga aattctggat tattaggaaa aataaagagg tagtagacaa 180
gaattggaga tactttctat caagattggt ctattatgct tggccatttc ttgtttgacc 240
caagtacttc ttgaaatcta gagtttgctg tgtgtgatgt ggtgtgtgtt tgtgtcacca 300
aaaaatctca ttagtcaaaa ctgaaatttt atttattaac tgacctacta aaaaatgata 360
gttctctgtg tgtgatgtgt gcttgtgtca ccaaaaaatct tgatttgata gagtttttat 420
ttatttatta actgacctac tacaaatcta ttgtgtatg ctatgtgtgt ctgtatcacc 480
tgaaatgcaa tgtcttcttc ttgttgttc ttgatctaac acgtgagctc atgtcaacag 540

```

&lt;210&gt; 2

&lt;211&gt; 614

&lt;212&gt; DNA

<213> *Oryza sativa*

&lt;400&gt; 2

```

ccgcgccagc ggaagcgccc ccaagttcat ccgcaagggt cggaaccttc tccttaatct 60

```

2 / 3

actogtcttt gctcttgctc tttttctttt gtgtcccttt cttgtgtgtg cgtttgcatg 120  
 agcccgaaat tgatctgcta gtgcacagta cagtcagata cactgaaacg atctggaaat 180  
 tctggattat taggaaaaat aaagaggtag tagacaagaa ttggagatac ttctatcaa 240  
 gattggtcta ttatgcttgg ccatttcttg tttagaccaa gtacttcttt gaatctagag 300  
 tttgctgtgt gtgatgtggt gtgtgtttgt gtcacaaaaa atcttcatta gctaaaaactg 360  
 aaattttatt tattaactga cctactaaaa atgtagagtt cctgtgtgtg gatgtgtgct 420  
 tgtgtcacca aaaatcttga ttgatagag tttttatita tttaataact gacctactac 480  
 aaatctattg ctgtatgcta tgttgtgtctg tatcacctga aatgcaatgt cttcttcttt 540  
 gttgttcttg atctaacacg tgagctcatg tcaacagttt tgggggggga ttgaggacac 600  
 tgtgggtgtc ggca 614

&lt;210&gt; 3

&lt;211&gt; 173

&lt;212&gt; DNA

<213> *Oryza sativa*

&lt;400&gt; 3

gtaagcccag tgtgcttagg ctaagcgac tagagcttct tgctgcttg cttctctcc 60  
 gctcagatct gcttgcttgc ttgcttcgct agaaccctac tctgtgctgc gagtgtcgct 120  
 gcttcgtctt ccttctctaa gttcgatctg attgtgtgtg tgggggggag cag 173

&lt;210&gt; 4

&lt;211&gt; 27

&lt;212&gt; DNA

<213> *Oryza sativa*

&lt;400&gt; 4

aagtcccccg ggccgcgcca gcggaag

27

&lt;210&gt; 5

3 / 3

&lt;211&gt; 27

&lt;212&gt; DNA

<213> *Oryza sativa*

&lt;400&gt; 5

atgcttgata tctgccgaca cccacag

27